Single Cell Omics Market Forecast (2026-2033) | Advanced Sequencing, Multi-Omics & Industry Opportunities

DataM Intelligence has released its latest Single Cell Omics Market Size 2026 research report, offering actionable market intelligence to help businesses identify high-growth opportunities, strengthen competitive positioning, and navigate evolving industry trends. The report delivers a comprehensive analysis of market size, revenue forecasts, CAGR, regional performance, and detailed segment-level insights. It also examines the key growth drivers, emerging market opportunities, investment potential, and competitive dynamics shaping the future of the global Single Cell Omics market, enabling stakeholders to make informed strategic decisions.

Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/single-cell-omics-market?kb

United States: Recent Industry Developments

✅ June 2026: Illumina launched the StrataMap Spatial Solution, enabling true single-cell resolution spatial transcriptomics for advanced oncology, neuroscience, and precision medicine research.

✅ June 2026: Weill Cornell Medicine and the New York Genome Center introduced D&D-seq, a breakthrough technology enabling high-throughput single-cell multi-omics mapping of DNA-protein interactions.

✅ June 2026: Samsung Electronics invested US$175 million in U.S.-based Element Biosciences to accelerate commercialization of next-generation sequencing and multi-omics technologies.

✅ January 2026: Researchers introduced the OKR-CELL foundation model, integrating large language models with single-cell multi-omics to improve cell annotation and cross-modal biological analysis.

Download Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/single-cell-omics-market?kb

List of Key Players 2026:

CYTENA GmbH, 10x Genomics, Becton, Dickinson and Company, CELLENION, Bio-Rad Laboratories Inc, Mission Bio, Standard BioTools Inc, Nanostring, Takarabio, BGI Genomics Co

Key Strategic Growth Forecast Projections 2026:

The Global Single Cell Omics Market is poised for robust growth during the 2026-2033 forecast period, driven by increasing maintenance demand, strategic investments, and ongoing technological advancements. Following steady expansion in 2025, the market is expected to witness stronger adoption across key industries, supported by evolving competitive strategies and growing opportunities for long-term revenue generation. The latest outlook highlights emerging market trends, innovation, and the factors shaping the future of the Single Cell Omics industry.

Key Strategic Developments 2025-2026:

For instance, in June 2026, 10x Genomics, a U.S.-based life sciences technology company, expanded its single-cell multiomics portfolio with advanced workflows that integrate gene expression, chromatin accessibility, and immune profiling, enabling researchers to gain deeper biological insights from individual cells.

Some of the key players focused on strengthening strategic collaborations. In May 2026, Illumina partnered with leading research institutions to accelerate adoption of next-generation sequencing solutions for single-cell genomics, supporting large-scale precision medicine and translational research initiatives.

Several companies also introduced innovative analytical solutions. In April 2026, Standard BioTools Inc. (formerly Fluidigm) launched enhanced single-cell proteomics and spatial biology workflows designed to improve biomarker discovery and high-resolution cellular analysis for oncology and immunology research.

Companies continued investing in acquisitions to expand their technology capabilities. In March 2026, Bio-Techne Corporation acquired a genomics technology company to strengthen its single-cell and spatial biology portfolio, expanding its capabilities in advanced life science research.

Product innovation remained a key growth strategy. In February 2026, Parse Biosciences introduced an upgraded single-cell RNA sequencing solution with higher throughput and improved scalability, enabling researchers to analyze millions of cells in a single experiment.

Research collaborations also accelerated market growth. In January 2026, Mission Bio expanded collaborations with leading cancer research centers to advance single-cell DNA sequencing applications for precision oncology, measurable residual disease (MRD) detection, and hematologic cancer research.

How Our Market Research Process Works:

The Global Single Cell Omics Market research report provides comprehensive strategic insights developed through a combination of in-depth primary research and extensive secondary analysis. It offers a detailed assessment of the key market dynamics, including industry trends, regulatory developments, competitive landscape, customer demand shifts, and historical market performance. The report also examines emerging technologies, innovation pipelines, and advancements across related industries that are accelerating the adoption of Single Cell Omics solutions. Additionally, it identifies high-growth opportunities, investment prospects, potential market risks, and operational challenges, equipping stakeholders with actionable intelligence to support informed decision-making and sustainable business growth in a rapidly evolving market.

Funding/M&A/partnerships 2025-2026:

• June 2026: Merck KGaA signed a definitive agreement to acquire Bio-Techne for US$11.3 billion, strengthening its life science tools portfolio, including multi-omics and single-cell research capabilities.

• January 2026: Illumina completed its acquisition of SomaLogic, expanding its proteomics and integrated multi-omics portfolio to accelerate single-cell and precision medicine research.

Request Strategic Market Customization: https://datamintelligence.com/customize/single-cell-omics-market?kb

Japan: Recent Industry Developments

✅ June 2026: biomy Inc. partnered with 10x Genomics to develop AI-driven Virtual Cell foundation models using Xenium spatial biology data for biomarker discovery and therapeutic response prediction.

✅ June 2026: Kyoto University's ASHBi SignAC hosted a technology seminar with Singleron Biotechnologies, showcasing integrated single-cell omics platforms for transcriptomics, immune profiling, and pathogen detection.

✅ May 2026: Kyoto University's ASHBi SignAC organized a technology seminar featuring Scienion GmbH, highlighting advanced single-cell genomics sample preparation and analysis technologies.

✅ January 2026: Kyoto University's ASHBi SignAC held a technology seminar with Syncell Inc. and SCRUM Inc., focusing on next-generation single-cell genome analysis and research workflows.

Major Segments Opportunity 2026:

By Product Type: Single-cell Genomics, Single-cell Proteomics, Single-cell Metabolomics, Single-cell Transcriptomics

By Application: Oncology, Cell Biology, Neurology, Immunology, Others

By End User: Pharmaceutical & Biotechnology companies, Academic and Research Organizations, Hospitals and Diagnostic laboratories, Others

Regional Growth Intelligence for Market:

⇥ North America - Leading market driven by advanced genomics research infrastructure, strong government and private funding, and widespread adoption of single-cell sequencing technologies across academic and biopharmaceutical research.

⇥ Europe - Growth supported by increasing precision medicine initiatives, collaborative genomics research programs, and rising investments in biotechnology and translational research.

⇥ Asia-Pacific - Fastest-growing region fueled by expanding life sciences research, increasing healthcare investments, growing biotechnology industries, and rising adoption of advanced omics technologies in China, Japan, and India.

⇥ Middle East & Africa - Emerging market supported by expanding biomedical research capabilities, improving healthcare infrastructure, and increasing investments in genomic medicine and research collaborations.

⇥ South America - Steady growth driven by expanding genomics research, increasing academic partnerships, government support for life sciences, and growing adoption of precision medicine across the healthcare sector.

Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=single-cell-omics-market?kb

Market Drivers 2026:

Growing Demand for Precision Medicine - Single cell omics enables detailed analysis of individual cells, supporting personalized therapies, targeted drug development, and improved patient outcomes.

Rising Investments in Genomics and Life Science Research - Increased funding from governments, research institutions, and biotech companies is accelerating the adoption of advanced single-cell analysis technologies.

Technological Advancements in Sequencing Platforms - Innovations in next-generation sequencing (NGS), microfluidics, and bioinformatics are improving data accuracy, scalability, and reducing analysis time.

Expanding Applications in Cancer and Immunology Research - The need to understand cellular heterogeneity in cancer, immune disorders, and rare diseases is driving widespread use of single cell omics in biomedical research.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.